BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

366 related articles for article (PubMed ID: 32823281)

  • 1. Antifungal efficacy of atorvastatin-containing emulgel in the treatment of oral and vulvovaginal candidiasis.
    de Oliveira Neto AS; Souza ILA; Amorim MES; de Freitas Souza T; Rocha VN; do Couto RO; Fabri RL; de Freitas Araújo MG
    Med Mycol; 2021 May; 59(5):476-485. PubMed ID: 32823281
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antifungal activities of two new azasordarins, GW471552 and GW471558, in experimental models of oral and vulvovaginal candidiasis in immunosuppressed rats.
    Martinez A; Ferrer S; Santos I; Jimenez E; Sparrowe J; Regadera J; De Las Heras FG; Gargallo-Viola D
    Antimicrob Agents Chemother; 2001 Dec; 45(12):3304-9. PubMed ID: 11709301
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cinnamaldehyde inhibits Candida albicans growth by causing apoptosis and its treatment on vulvovaginal candidiasis and oropharyngeal candidiasis.
    Chen L; Wang Z; Liu L; Qu S; Mao Y; Peng X; Li YX; Tian J
    Appl Microbiol Biotechnol; 2019 Nov; 103(21-22):9037-9055. PubMed ID: 31659418
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel Preclinical Study of Galloylquinic Acid Compounds from
    Al-Madboly LA; Abd El-Salam MA; Bastos JK; El-Shorbagy SH; El-Morsi RM
    Microbiol Spectr; 2022 Oct; 10(5):e0272421. PubMed ID: 35972130
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The anti-staphylococcal fusidic acid as an efflux pump inhibitor combined with fluconazole against vaginal candidiasis in mouse model.
    Gomaa SE; Abbas HA; Mohamed FA; Ali MAM; Ibrahim TM; Abdel Halim AS; Alghamdi MA; Mansour B; Chaudhary AA; Elkelish A; Boufahja F; Hegazy WAH; Yehia FAA
    BMC Microbiol; 2024 Feb; 24(1):54. PubMed ID: 38341568
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [INVESTIGATION ON ANTIFUNGAL SUSCEPTIBILITY OF CANDIDA YEASTS IN PREGNANT PATIENTS WITH CONFIRMED VULVOVAGINAL CANDIDIASIS AND THEIR NEWBORNS.].
    Chokoeva A; Kouzmanov A; Ivanova Z; Zisova L; Amalie G; Petleshkova P; Miteva-Katrandzhieva T; Krasteva M; Uchikova E
    Akush Ginekol (Sofiia); 2016; 55(4):20-29. PubMed ID: 29370489
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro study on the potential fungicidal effects of atorvastatin in combination with some azole drugs against multidrug resistant Candida albicans.
    Mahmoud DE; Faraag AHI; Abu El-Wafa WM
    World J Microbiol Biotechnol; 2021 Oct; 37(11):191. PubMed ID: 34632522
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro susceptibility of Candida albicans clinical isolates to eight antifungal agents in Ouagadougou (Burkina Faso).
    Zida A; Yacouba A; Bamba S; Sangare I; Sawadogo M; Guiguemde T; Kone S; Traore LK; Ouedraogo-Traore R; Guiguemde RT
    J Mycol Med; 2017 Dec; 27(4):469-475. PubMed ID: 28754462
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vivo activity of terpinen-4-ol, the main bioactive component of Melaleuca alternifolia Cheel (tea tree) oil against azole-susceptible and -resistant human pathogenic Candida species.
    Mondello F; De Bernardis F; Girolamo A; Cassone A; Salvatore G
    BMC Infect Dis; 2006 Nov; 6():158. PubMed ID: 17083732
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quercetin Assists Fluconazole to Inhibit Biofilm Formations of Fluconazole-Resistant Candida Albicans in In Vitro and In Vivo Antifungal Managements of Vulvovaginal Candidiasis.
    Gao M; Wang H; Zhu L
    Cell Physiol Biochem; 2016; 40(3-4):727-742. PubMed ID: 27915337
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An Azole-Tolerant Endosomal Trafficking Mutant of Candida albicans Is Susceptible to Azole Treatment in a Mouse Model of Vaginal Candidiasis.
    Peters BM; Luna-Tapia A; Tournu H; Rybak JM; Rogers PD; Palmer GE
    Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28348159
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Spilanthol as a promising antifungal alkylamide for the treatment of vulvovaginal candidiasis.
    Fabri RL; Freitas JCO; Lemos ASO; Campos LM; Diniz IOM; Pinto NCC; Silva TP; Palazzi C; Marchesini P; Monteiro C; Barbosa AF; Carvalho MG; Chedier LM; Araújo MGF; Apolônio ACM; Rocha VN; Melo RCN; Pinto PF
    Med Mycol; 2021 Dec; 59(12):1210-1224. PubMed ID: 34468763
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The in vivo anti-Candida albicans activity of flavonoids.
    Nguyen W; Grigori L; Just E; Santos C; Seleem D
    J Oral Biosci; 2021 Jun; 63(2):120-128. PubMed ID: 33839266
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proanthocyanidin polymeric tannins from Stryphnodendron adstringens are effective against Candida spp. isolates and for vaginal candidiasis treatment.
    de Freitas ALD; Kaplum V; Rossi DCP; da Silva LBR; Melhem MSC; Taborda CP; de Mello JCP; Nakamura CV; Ishida K
    J Ethnopharmacol; 2018 Apr; 216():184-190. PubMed ID: 29325916
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Determining Susceptibility in
    Sobel JD; Akins R
    Antimicrob Agents Chemother; 2022 Jun; 66(6):e0236621. PubMed ID: 35604210
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activities of Nerol, a natural plant active ingredient, against Candida albicans in vitro and in vivo.
    Wang Z; Yang K; Chen L; Yan R; Qu S; Li YX; Liu M; Zeng H; Tian J
    Appl Microbiol Biotechnol; 2020 Jun; 104(11):5039-5052. PubMed ID: 32248438
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of curcumin in the treatment of experimental vulvovaginal candidiasis.
    Andrade JT; Fantini de Figueiredo G; Cruz LF; Eliza de Morais S; Souza CDF; Pinto FCH; Ferreira JMS; Araújo MGF
    Rev Iberoam Micol; 2019; 36(4):192-199. PubMed ID: 31757595
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparative investigation of azole susceptibility in Candida isolates from vulvovaginal candidiasis and recurrent vulvovaginal candidiasis patients in Ghana.
    Adjapong G; Hale M; Garrill A
    Med Mycol; 2017 Aug; 55(6):686-689. PubMed ID: 27838642
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Guideline: vulvovaginal candidosis (AWMF 015/072), S2k (excluding chronic mucocutaneous candidosis).
    Mendling W; Brasch J; Cornely OA; Effendy I; Friese K; Ginter-Hanselmayer G; Hof H; Mayser P; Mylonas I; Ruhnke M; Schaller M; Weissenbacher ER
    Mycoses; 2015 Mar; 58 Suppl 1():1-15. PubMed ID: 25711406
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Positive interaction of nikkomycins and azoles against Candida albicans in vitro and in vivo.
    Hector RF; Schaller K
    Antimicrob Agents Chemother; 1992 Jun; 36(6):1284-9. PubMed ID: 1416829
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.